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Purpose
Non-infectious uveitis (“uveitis”) is an important cause of
visual loss amongst children. Although TNFa inhibitors
(anti-TNFa) are increasingly used to treat pediatric uvei-
tis, the outcomes of treatment with these agents have
been poorly described. We are studying the largest, and
only multicenter, group of patients with pediatric uveitis
in order to more precisely estimate the outcomes of
treatment with anti-TNFa and to evaluate which factors
increase the likelihood of achieving uveitis quiescence
after treatment. The final cohort will include subjects
from the five-center Systemic Immunosuppressive Ther-
apy for Eye Diseases Cohort Study, The Children’s Hos-
pital of Philadelphia (CHOP), and Hershey Medical
Center. Here we report preliminary results from subjects
at CHOP.
Methods
This cohort included a child if (s)he was <19 years old at
treatment outset, was treated with his/her first ever anti-
TNFa while having active uveitis, and had uveitis activity
information within 15 days of starting the drug. A child
could also be treated with steroids and/or methotrexate.
Active uveitis was defined according to the SUN Working
Group (2005). Quiescence was defined as having inactive
uveitis in both eyes at sequential ophthalmologic exams
≥28 days apart while no longer receiving steroids. Survival
analysis evaluated time to quiescence.
Results
Of the 109 children treated for uveitis at CHOP, 39 have
been analyzed who were treated with anti-TNFa. Eighteen
met inclusion criteria and had adequate follow-up infor-
mation. Of these, 67% were female, 56% were Caucasian,
23% were diagnosed <6 years, 33% had juvenile idiopathic
arthritis (JIA), 11% had oligo-articular JIA, 47% had painful
uveitis, and 22% were ANA positive. All of those who were
ANA positive were female. While there was a statistically
significant association between female sex and JIA
(p=0.034) there was not an association between ANA posi-
tivity and oligo-articular JIA (p=0.32) or male gender and
painful uveitis (p=0.84). The total analysis time was 20.8
years (0.3-4.3 years/patient). The probability of a child
achieving quiescence was 0 at 3 months; 0.33 at 6 months
(95% confidence interval 0.27, 0.73); and 0.47 at 12 months
(0.23, 0.73). Fifty percent of subjects achieved remission by
13 months (6.3, 19.4). Ultimately, 85% of the cohort
achieved quiescence. Achievement of success was not
associated with sex, race, age <6 years at diagnosis, JIA,
oligoarticular JIA, painful uveitis, or ANA status. Because
16/18 children were treated with infliximab, the impact of
anti-TNFa type was not explored.
Conclusion
In this preliminary study, treatment with a first-ever
anti-TNFa resulted in quiescence in 47% of subjects at
12 months. This rate is slower than might be expected
based on other studies. This may reflect our more strin-
gent definition of remission. Other studies have used
achievement of uveitis inactivity alone or inactivity with
a decrease in steroid as outcome measures; we defined
quiescence as withdrawal of all steroids. Given the lim-
ited sample size, we were unable to identify independent
factors associated with quiescence. We plan to identify
associated factors and develop an explanatory model of
success with our final cohort of >100 patients.
Disclosure
Melissa A. Lerman: None; Monte Mills: None; Marshall
Joffe: None; Terri H. Finkel: None; Sean Hennessy:
None; John H. Kempen: None.
Author details
1The Children’s Hospital of Phiadelphia, Philadelphia, PA, USA. 2University of
Pennsylvania School of Medicine, Philadelphia, PA, USA.
Published: 13 July 2012
1The Children’s Hospital of Phiadelphia, Philadelphia, PA, USA
Full list of author information is available at the end of the article
Lerman et al. Pediatric Rheumatology 2012, 10(Suppl 1):A79
http://www.ped-rheum.com/content/10/S1/A79
© 2012 Lerman et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.
doi:10.1186/1546-0096-10-S1-A79
Cite this article as: Lerman et al.: Response of pediatric uveitis to TNFa
inhibitors. Pediatric Rheumatology 2012 10(Suppl 1):A79.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Lerman et al. Pediatric Rheumatology 2012, 10(Suppl 1):A79
http://www.ped-rheum.com/content/10/S1/A79
Page 2 of 2
